title: Ex-Vivo percutaneous absorption of enrofloxacin: Comparison of LMOG organogel vs. pentravan cream.
abstract: The objective of this study was to investigate the percutaneous absorption of enrofloxacin from two base formulations, Pentravan cream and LMOG organogel. Ex-vivo experiments were carried out on pig ear skin. The percutaneous permeation through pig skin of two formulations containing 5 wt% of enrofloxacin was measured and compared using Franz diffusion cells. At appropriate intervals up to 120 h, diffusion samples were taken and analyzed using HPLC assays. Permeation profiles were established and the parameters Tlag and flux values were calculated. In this ex-vivo study, the flux values were 0.35 μgcm(-2)h(-1) for Pentravan and 1.22 μgcm(-2)h(-1) for LMOG organogel, corresponding respectively to 7.9 % and 29.3 % of enrofloxacin absorbed after 120 h by these formulations. The lag time (T lag) of Pentravan and organogel were 6.32 and 0.015 h respectively. The absorption time to reach the antibiotic concentration of enrofloxacin (2 μgmL(-1)) in the receptor was 60 h with Pentravan and 30 h with the organogel, suggesting more effective treatment by the latter. Enrofloxacin contained in organogel could be absorbed through pig ear skin 3.7 times greater than that in Pentravan (commercial formulation). This study demonstrates the perspective of organogel formulations as potential drug delivery systems.
authors.affiliation: Université Claude Bernard Lyon 1, EA 4169 "Aspects fondamentaux, cliniques et thérapeutique de la fonction barrière cutanée", SFR Lyon-Est Santé, INSERM US 7, CNRS UMS 3453, ISPB, 8 avenue Rockefeller, 69373 Lyon Cedex 08, France. Electronic address: plamen.kirilov@univ-lyon1.fr.
authors.forename: Plamen
authors.initials: P
authors.lastname: Kirilov
authors.affiliation: Université Claude Bernard Lyon 1, EA 4169 "Aspects fondamentaux, cliniques et thérapeutique de la fonction barrière cutanée", SFR Lyon-Est Santé, INSERM US 7, CNRS UMS 3453, ISPB, 8 avenue Rockefeller, 69373 Lyon Cedex 08, France.
authors.forename: Van Hung
authors.initials: VH
authors.lastname: Tran
authors.affiliation: Université Claude Bernard Lyon 1, EA 4169 "Aspects fondamentaux, cliniques et thérapeutique de la fonction barrière cutanée", SFR Lyon-Est Santé, INSERM US 7, CNRS UMS 3453, ISPB, 8 avenue Rockefeller, 69373 Lyon Cedex 08, France.
authors.forename: Alban
authors.initials: A
authors.lastname: Ducrotté-Tassel
authors.affiliation: Université Claude Bernard Lyon 1, EA 4169 "Aspects fondamentaux, cliniques et thérapeutique de la fonction barrière cutanée", SFR Lyon-Est Santé, INSERM US 7, CNRS UMS 3453, ISPB, 8 avenue Rockefeller, 69373 Lyon Cedex 08, France.
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Salvi
authors.affiliation: Ecole Nationale Vétérinaire d'Alfort, Unité de Pharmacie-Toxicologie, Département des Sciences Biologiques et Pharmaceutiques, Laboratoire Central d'Analyse et d'Appui Scientifique et Technique, Institut de Recherche Clinique Animale, 7 avenue du Général de Gaulle Bâtiment Blin, 94704 Maisons-Alfort Cedex, France.
authors.forename: Sébastien
authors.initials: S
authors.lastname: Perrot
authors.affiliation: Université Claude Bernard Lyon 1, EA 4169 "Aspects fondamentaux, cliniques et thérapeutique de la fonction barrière cutanée", SFR Lyon-Est Santé, INSERM US 7, CNRS UMS 3453, ISPB, 8 avenue Rockefeller, 69373 Lyon Cedex 08, France.
authors.forename: Marek
authors.initials: M
authors.lastname: Haftek
authors.affiliation: Université Claude Bernard Lyon 1, EA 4169 "Aspects fondamentaux, cliniques et thérapeutique de la fonction barrière cutanée", SFR Lyon-Est Santé, INSERM US 7, CNRS UMS 3453, ISPB, 8 avenue Rockefeller, 69373 Lyon Cedex 08, France; CHU de Lyon, Unité de Pharmacocinétique Clinique, Place d'Arsonval, 69437 Lyon Cedex 03, France.
authors.forename: Roselyne
authors.initials: R
authors.lastname: Boulieu
authors.affiliation: Université Claude Bernard Lyon 1, EA 4169 "Aspects fondamentaux, cliniques et thérapeutique de la fonction barrière cutanée", SFR Lyon-Est Santé, INSERM US 7, CNRS UMS 3453, ISPB, 8 avenue Rockefeller, 69373 Lyon Cedex 08, France; Service Pharmaceutique, Plateforme FRIPHARM, Groupement Hospitalier Edouard Herriot, Hospices Civils de Lyon, 5 Place d'Arsonval, F-69437 Lyon Cedex 03, France.
authors.forename: Fabrice
authors.initials: F
authors.lastname: Pirot
mesh_terms: D000279:Administration, Cutaneous; D000818:Animals; D002626:Chemistry, Pharmaceutical; D000077422:Enrofloxacin; D024841:Fluoroquinolones / Q000008:administration & dosage / Q000737:chemistry* / Q000378:metabolism*; D005782:Gels; D009924:Organ Culture Techniques; D012869:Skin Absorption / Q000187:drug effects* / Q000502:physiology; D063465:Skin Cream / Q000008:administration & dosage / Q000737:chemistry* / Q000378:metabolism*; D013552:Swine
chemical_list: D024841:Fluoroquinolones; D005782:Gels; D000077422:Enrofloxacin
keywords: 12-hydroxystearic acid (PubChem CID: 7789); Demineralized water (PubChem CID: 962); Enrofloxacin; Enrofloxacin (PubChem CID: 71188); Glycerol (PubChem CID: 753); HPLC quantification; In-vitro percutaneous absorption; Isopropyl myristate (PubChem CID: 8042); LMOG organogel; Oleic acid (PubChem CID: 445639); Pentravan(®); Perchloric acid (PubChem CID: 24247); Phosphate-Buffered Saline (PubChem CID: 249785514); Polyoxyl 40 stearate (PubChem CID: 24762); Simethicone (PubChem CID: 6433516); Soja lecithin (PubChem CID: 57369748)